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Cross-talks between the kidneys and the central nervous 
system in multiple sclerosis 
 
 
Abstract 
Multiple sclerosis (MS) is an inflammatory demyelinating disease, which is considered as 
a common autoimmune disorder in young adults. A growing number of evidences 
indicated that the impairment in non-neural tissues plays a significant role in pathology of 
MS disease. There are bidirectional relationship, metabolic activities and functional 
similarity between central nervous system (CNS) and kidneys which suggest that kidney 
tissue may exert remarkable effects on some aspects of MS disorder and CNS impairment 
in these patients compels the kidney to respond to central inflammation. Recently, it has 
been well documented that hormonal secretion possesses the important role on CNS 
abnormalities. In this regard, due to the functional similarity and significant hormonal and 
non-hormonal relationship between CNS and kidneys, we hypothesized that kidneys exert 
significant effect on initiation, progression or amelioration of MS disease which might be 
regarded as potential therapeutic approach in the treatment of MS patients in the future. 
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Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous 
system (CNS) which mainly affects young people worldwide (1). Numerous studies 
suggested that MS patients show several impairments including vascular, musculoskeletal, 
gastrointestinal, ocular (visual), mental, renal problems which lead to negative impacts on 
quality of life (2). In fact, the systemic inflammation and overproduction cytokines 
contribute to the pathogenesis of multiple organs dysfunction and failure (3). In addition, it 
has been shown that injury in one organ can lead to injury in a distant organ (4). In this 
line peripheral inflammatory factors such as TNF-α plays an important role in brain 
damage of animals with experimental autoimmune encephalomyelitis (EAE), as a model 
of MS. Indeed, dendritic spines and axonal buttons loss were observed 7 days after EAE 
induction. Moreover, synaptic instability also occurred before T-cell infiltration and 
microglia activation in the CNS. It seems that peripheral production of TNF-α leads to 
sensory and cognitive defects. Therefore, anything that increases peripheral but not central 
TNF-α production can potentially induce CNS damage (5). Recent studies have indicated 
that non-neural impairments might play an important role in MS initiation and progression. 
For instance Nouri et al., (2014) reported that overexpression of zonulin, as tight junction 
modulator protein, can increase intestinal permeability in EAE model. It has been 
suggested that entrance of intraluminal antigens into systemic circulation triggers antigen 
interaction with immune cells. Furthermore, increased intestinal permeability may lead to 
inflammation and morphological changes in ileum and jejunum cells and initiate multi-
organ failure which causes the autoimmune responses (1).  
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Several studies also describe the bidirectional 
relationship between the brain and kidneys. In this regard, 
after neurological dysfunction or renal failure, the 
pathological mechanism including alteration in microscopic 
anatomy, vasoregulation and hormonal pathways can cause 
chronic degeneration changes in both organs (3). The 
aforementioned examples are sufficed to hypothesize the 
possible functional relationship among kidneys, CNS and 
immune system in the initiation and progression of MS 
disorder. Undoubtedly, the kidneys exert important 
physiological functions in the human body such as removing 
waste products, electrolyte balance and blood pressure 
regulation.  
Besides, kidneys are involved in the production and 
secretion of several hormones including erythropoietin 
(EPO), renin, 1, 25-dihydroxyvitamin D and also a newly 
found anti-aging protein which is called Klotho (6). Based 
on the critical role of kidneys in homeostasis maintenance, 
one might speculate that, functional impairment in kidneys 
may lead to significant effects in the CNS. On the other 
hand, this hypothesis may provide the new therapeutic 
approaches for treatment of MS disease. In this regard, if the 
hypothesis is proven to be correct, monitoring of kidney 
function is necessary for MS patients and helps them to 
avoid progression of MS disease. It can also be helpful to use 
recombinant EPO and Klotho as anti-inflammatory and anti-
aging hormones in order to compensate the impaired 
hormonal functions of kidneys.  
Evaluation of the hypothesis 
According to aforementioned data and based on the role 
of kidneys as endocrine/metabolic organ in expression of the 
secretory proteins, kidneys show a noticeable similarity to 
the choroid plexus of CNS. Interestingly, kidneys and 
choroid plexus share nearly 211 common proteins. Since the 
physiological role of choroid plexus in maintaining the 
chemical balance of cerebrospinal fluid (CSF) is analogous 
to the function of kidneys in blood, choroid plexus has been 
introduced as the ‘kidney’ of the brain (7). There are several 
studies proving the correlation between the brain and 
kidneys. For instance, patients with chronic kidney disease 
(CKD) are potentially susceptible to impairment of 
cognition. Furthermore, brain imaging studies demonstrated 
that white matter lesions occur in CKD patients. The 
possible explanation for brain lesions in CKD patients could 
be attributed to uremia, calcium-phosphate imbalance and 
inflammatory responses that have occurred over time after 
kidney damage (8). Acute kidney injury (AKI) is the other 
renal disorder leading to amplification of damage in brain 
through cytokine production and oxidative stress (9, 10). 
Secretion of pro-inflammatory chemokines (CXCL 1, 2 and 
3) and cytokines (IL-1, 6, 10, 18, INF-γ and TGF-β) from 
kidney and  activation of Toll like receptor 2 and 4 in 
astrocyte, microglia and neurons during AKI can contribute 
to the BBB disruption and brain local inflammation. This is 
in contrast to the traditional concept that the CNS is isolated 
from the immune system (9). Several studies also indicated 
that brain injury leads to changes in the kidney function. Cell 
death in the brain alters distant organs through hemodynamic 
instability, increase immunological complications and 
hormonal disturbance (4, 11, 12). It has been suggested that 
brain injury directly affects the kidneys by 3 mechanisms: 
1) Enhancement of  neural and renal sympathetic activity 
2) Hypothalamo-pituitary axis 3) Intra cranial inflammatory 
cytokines cross the BBB through BBB-deficient areas into 
the systemic circulation and elevate the systemic 
inflammation and induce the oxidative stress process (13). 
Another study on progressive type of MS showed that the 
estimated glomerular filtration rate (eGFR) of patients is 
significantly lower than healthy individuals. Although 
reduction in eGFR revealed disruption in kidney function, 
but unexpectedly, their serum creatinine was normal or lower 
than normal. In the progressive type of MS disease, high 
volume of muscle mass is lost which leads to serum 
creatinine level decline. Therefore, this effect can mask the 
real changes in eGFR (14). 
Additionally, there are significant hormonal-mediated 
cross-talks between CNS and kidneys in normal or abnormal 
status. In this context, the following provided evidences in 
support to hormonal relationship between kidneys and brain.  
Renin angiotensin system (RAS) 
RAS is an important hormonal system in cerebrorenal 
connection. Low blood pressure stimulates juxtaglomerular 
cells to secrete Renin. In addition, renin converts 
angiotensinogen to angiotensin I (Ang I).  In turn, Ang I is 
cleaved to Ang II by angiotensin-converting enzyme (ACE). 
Although it is worth mentioning that variety of receptors has 
been found for Ang II on the surface of kidney, heart, brain 
and immune cells. Ang II receptors initiate inflammation and 
increase blood pressure. 
 Furthermore, ACE and Ang II receptor type 1 (AT1R) 
increase antigen presenting cell and making central 
inflammatory response(15). Salt intake and sodium ion 
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accumulation can stimulate renal and cerebral RAS, which 
connect to each other by afferent and efferent sympathetic 
nerves. The reaction has been termed the “reno-cerebral RAS 
axis“. This system activates NADPH oxidase and increases 
free radical production, inflammatory cell population and 
blood brain barrier (BBB) permeability (16, 17) In patients 
with CKD disease, kidney mass, enzymes activity and 
secreted factor significantly decreased. Accordingly, the 
amount of enzymes such as 1-alpha-hydroxylase (which 
activates vitamin D) and hematopoietic hormone EPO are 
influenced. Thereby reducing vitamin D and EPO levels, the 
renin expression and RAS activity increase and stimulate 
immune system and initiate neuronal lesion (18). 
Erythropoietin (EPO) 
Although brain, liver and uterus are able to synthesize 
EPO, kidney is the main source for secretion of EPO which 
acts systemically. Unlike the kidneys, there is paracrine 
EPO/ EPO receptor in brain that acts independently from the 
endocrine system (19). In the CNS, EPO acts as anti-
apoptotic, anti-inflammatory, anti-oxidant and neurotropic 
factor and exerts important role in oligodendrocyte 
progenitor cells proliferation (20, 21).  
Therefore, EPO deficiency or insufficiency has adverse 
effects on human brain. Former assumption implies that 
large molecule such as EPO cannot transfer across the BBB. 
Brines et al. (2000) indicated that high dose intravenous (IV) 
injection of recombinant EPO can cause EPO passing 
through BBB.  
These results suggesting EPO as neuroprotective agent, is 
able to alleviate the severity of disease in animal models of 
focal brain ischemia, concussive brain injury, EAE and 
kainate-induced seizures. In fact, EPO delays the TNFα level 
overexpression, ameliorates gliosis and reduced the 
infiltration of inflammatory factors into spinal cord (20, 22). 
De-he et al. indicated that serum EPO level in MS patients 
complicated with anemia was lower than iron deficiency 
anemia (IDA) (23). Of note, because of kidney failure, EPO 
secretion decreased in these patients. According to the earlier 
data, it is plausible that EPO consumption is a compensatory 
response to immune stimulation or inflammation in MS 
patients.  
Vitamin D 
Calcitriol or 1, 25-dihydroxy vitamin D is the active form 
of vitamin D that is produced in proximal tubules of the 
kidney by 1-alpha hydroxylase and supports the endocrine 
actions of vitamin D. Calcitriol is secreted into the systemic 
circulation and exert its effects in various tissues (24). It is 
beyond doubt that calcitriol has direct effect on brain and 
immune system.  Immune cells such as macrophages, 
monocytes and dendritic cells express vitamin D receptor 
(VDR) on their surface as well as all types of the CNS cells 
including neurons, oligodendrocytes and astrocytes. In 
addition, calcitriol binds to VDR and decreases the secretion 
of cytokines and regulates adaptive immunity in multiple 
ways (25). Studies on MS patients have shown that the 
expression level of vitamin D activator enzyme such as 1-
alpha hydroxylase is lower than normal persons. Based on 
the role of vitamin D in immune system modulation, these 
persons may be susceptible to autoimmune diseases (26). 
Furthermore, it has been shown that renal inflammation is 
associated with reduction in serum vitamin D metabolites. 
Besides, previous studies using vitamin D analogs have 
indicated that the endocrine vitamin D system may also 
contribute to immunomodulatory responses. Increase in 
serum 1, 25-dihydroxy vitamin D or 25-hydroxy vitamin D 
resulted in lower renal inflammation (24, 27).  As mentioned 
previously, people with kidney dysfunction have lower 
expression of 1-alpha hydroxylase, so it seems that the risk 
of MS disease is higher than normal persons in these 
patients.  
Klotho (KL) 
KL is an anti-aging protein which is mainly synthesized 
in kidneys, brain, parathyroid gland and heart. Among these 
tissues, the choroid plexus and kidneys are the most 
important regions for KL secretion. Basically two forms of 
KL were detected in the human body, including 
transmembrane KL (T- KL) and secreted Klotho (S-KL). 
The T- KL is a co-receptor for fibroblast growth factor 23 
(FGF23) signaling. In this way, FGF23 binds to the FGF23 
receptor with much higher affinity than FGF23 receptor or 
Klotho alone.  
This interaction suppresses 1-alpha-hydroxylase 
expression and 1, 25-dihydroxyvitamin-D production. The 
extracellular domain of T-KL is proteolyzed by ADAM10 
and ADAM17 which causes conversion of T-KL to the other 
form of KL. These fragments that are released to circulation 
system have been termed S-KL. S-KL have anti-
inflammatory and antioxidant activities and play an 
important anti-inflammatory role in the brain and kidney (28, 
29).  
 Emami Aleagha et al. in 2015 demonstrated that the CSF 
level of KL in patients suffering from relapsing-remitting 
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MS (RRMS) is significantly lower than control group (30). 
In 2016, they reported an evaluation of KL concentration in 
the serum of RRMS with prolonged duration is higher than 
control and new cases of MS disease. They suggested that, 
when MS disease lasts for a longer period, the regenerative 
pathways need to be more activated and so it might be 
responsible for increasing the serum level of KL (31). It 
means that the enhancement in S-KL production by the 
kidneys is a compensatory response to the neurodegenerative 
condition. Furthermore, the cleavage of T-KL for increasing 
the S-KL concentration, not only helps the immune system 
regulation, but also prevents the decline of 1, 25-
dihydroxyvitamin-D.   
How to test the hypothesis? 
Several strategies are possible to test this hypothesis. The 
first one is the assessment of renal function by performing 
routine laboratory test on the serum and urine. In this 
approach, kidney response to the CNS inflammation in MS 
patients can be assessed with the evaluation of the level of 
renal endocrine hormones such as KL and EPO. Since renal 
biopsy operation from MS patients is not ethical, so 
induction of EAE as a conventional model of MS disease is 
considered as the best strategy to study the inflammatory 
condition. 
 Structural alteration and the expression levels of 
aforementioned genes in the CNS and kidney in response to 
central inflammation can be evaluated with EAE model. 
CKD induction in rodents before EAE immunization is 
another way to determine susceptibility to EAE induction 
and evaluate intensity of lesions. 
Consequences of the hypothesis  
On the basis of similarities in hormonal activities in 
kidneys and CNS as well as the association between kidneys 
and brain in hemodynamic, hormonal and sympathetic 
aspects, we predict that pathophysiological alterations in the 
CNS can be led to dramatic response in the kidney tissue of 
MS patients.  
These responses may reduce the severity of the CNS 
injuries or increase the lesion area. In this regard, it is 
plausible that impairment in kidney's secretory functions 
might contribute to brain dysfunction in MS patients and 
vice versa. In contrast, it is also possible that the 
aforementioned renal responses by the kidneys in MS 
patients can exert the beneficial effects on the improvement 
of the disease. The metabolic cross-talk between kidneys and 
CNS is not limited to endocrine hormones but corroborated 
with factors such as KL and vitamin D. 
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